Aurobindo: Biosimilars Inflection Point Pushed, Pomalidomide Launch Set For Q4

China-Led Fall In Pen-G, 6-APA Prices

 
• By Vibha Ravi
  
Aurobindo Confident On Biosimilars But Recalibrates Inflection Point
Aurobindo Confident On Biosimilars But Recalibrates Inflection Point (Shutterstock)

More from Earnings

More from Business